Lantern Pharma (NASDAQ: LTRN) was highlighted in a Dallas Innovates article covering the 2025 BioNTX iC3 Summit, where industry leaders declared the traditional biotech model “broken.” The Dallas-based clinical-stage biopharmaceutical company, which leverages its RADR AI platform to transform oncology drug development, had CEO Panna Sharma serve as both moderator and panelist at the event.
Sharma was quoted in the piece: “The process of actually making drugs is still largely manual. We have the technology to change that, but the industry hasn’t adopted it fast enough.” The article emphasized Sharma’s view that AI-driven platforms like RADR can streamline discovery, accelerate clinical timelines, and reduce costs, directly addressing the summit’s call for innovation and efficiency.
By advancing a data-driven model, Lantern positions itself at the forefront of efforts to create a more sustainable future for biotech. The full article can be viewed at https://ibn.fm/DM9ur.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning platform, RADR, leverages over 200 billion oncology-focused data points and a library of more than 200 advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, the company has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate program.
The company’s lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. Its AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.
For more information on Lantern Pharma, visit the company’s newsroom at https://ibn.fm/LTRN.
